Tokyo, Japan – Nxera Pharma Co., Ltd. Has taken a significant step towards expanding access to its insomnia treatment, daridorexant, with the submission of a marketing authorisation application (MAA) to South Korea’s Ministry of Food and Drug Safety (MFDS). The application, filed on March 4, 2026, follows promising results from a Phase 3 clinical trial conducted in South Korea, demonstrating the drug’s efficacy in improving sleep patterns. This move signals Nxera Pharma’s commitment to addressing the growing need for effective insomnia treatments in the East Asian market.
Daridorexant, a dual orexin receptor antagonist, works by blocking the action of orexin, a neurotransmitter that promotes wakefulness. This mechanism helps to regulate the sleep-wake cycle, allowing individuals struggling with insomnia to fall asleep more easily and stay asleep longer. The Phase 3 trial data submitted to the MFDS showed statistically significant improvements compared to a placebo across key measures of sleep quality, including subjective total sleep time (sTST), subjective sleep onset latency (sLSO), and subjective wake after sleep onset (sWASO). According to the company, the study administered 50mg doses over a 28-day period.
Growing Demand for Insomnia Treatments in South Korea
The timing of this application is particularly relevant given the increasing prevalence of insomnia in South Korea. Estimates suggest that between 650 and 1,100 million people in the country suffer from the sleep disorder. Data from the Health Insurance Review and Assessment Service reveals a substantial 21% increase in patients treated for chronic insomnia between 2018 and 2022, highlighting a clear and growing unmet medical need. This rising trend is likely driven by factors such as increased stress levels, changing lifestyles, and an aging population.
Nxera Pharma anticipates receiving regulatory approval from the MFDS by 2027. While the company expects the South Korean filing to have a negligible impact on its consolidated financial results for the fiscal year ending December 2026, the long-term potential of the market is substantial. The company’s strategic move reflects a broader trend of pharmaceutical companies targeting emerging markets with innovative treatments.
Daridorexant’s Global Reach and Existing Approvals
Daridorexant is already approved and marketed in several key global markets, demonstrating its established safety and efficacy profile. In Japan, the drug is available under the brand name QUIVIVIQ through a partnership with Shionogi & Co., Ltd. It has also received regulatory approval in the United States, Canada, and multiple European nations. This widespread availability underscores the international recognition of daridorexant as a valuable treatment option for insomnia. The drug’s success in these markets provides a strong foundation for its potential launch in South Korea.
Clinical Trial Results: A Closer Gaze
The Phase 3 clinical trial in South Korea, which underpinned the MAA submission, demonstrated a favorable safety profile for daridorexant. Adverse event rates were reported at 13.41%, slightly lower than the 14.81% observed in the placebo group. This suggests that the drug is generally well-tolerated by patients. The trial’s positive results, with a p-value of less than 0.0001 for improvements in sTST, sLSO, and sWASO, provide compelling evidence of daridorexant’s effectiveness. These findings are crucial for securing regulatory approval and establishing the drug’s position in the South Korean market.
The dual orexin receptor antagonist mechanism of action distinguishes daridorexant from some other insomnia treatments. Orexin plays a critical role in regulating wakefulness, and by blocking its receptors, daridorexant helps to promote sleep. This targeted approach may offer advantages for patients who have not responded adequately to other therapies. The drug’s efficacy in improving multiple aspects of sleep quality – including falling asleep, staying asleep, and total sleep duration – further enhances its potential value for individuals struggling with insomnia.
Nxera Pharma’s Strategy and Future Outlook
Nxera Pharma’s decision to pursue regulatory approval in South Korea aligns with its broader strategy of expanding its global footprint and delivering innovative pharmaceutical solutions to patients worldwide. The company, traded on the Tokyo Stock Exchange under the ticker symbol 4565, has demonstrated a commitment to research and development, resulting in the successful launch of daridorexant in multiple markets. The company’s focus on addressing unmet medical needs, coupled with its strong clinical data, positions it for continued growth and success.
While Nxera Pharma anticipates minimal financial impact from the South Korean application in the short term, the long-term potential of the market is significant. The increasing prevalence of insomnia, coupled with a growing awareness of the importance of sleep health, is expected to drive demand for effective treatments. Nxera Pharma’s proactive approach to securing regulatory approval in South Korea demonstrates its commitment to serving the needs of patients in this important market.
Understanding Orexin and its Role in Sleep
Orexin, also known as hypocretin, is a neuropeptide that plays a crucial role in regulating wakefulness, arousal, and appetite. It is produced by a small group of neurons in the hypothalamus, a region of the brain involved in regulating various bodily functions. Orexin neurons project to multiple brain areas, including those involved in sleep-wake control, and their activation promotes wakefulness. In individuals with insomnia, orexin levels may be dysregulated, contributing to difficulties falling asleep and staying asleep. Daridorexant’s mechanism of action – blocking orexin receptors – helps to restore balance to the sleep-wake system.
The development of daridorexant represents a significant advancement in the treatment of insomnia. Traditional insomnia medications often work by suppressing brain activity, which can lead to side effects such as daytime drowsiness and cognitive impairment. Daridorexant’s targeted approach, focusing on the orexin system, offers a potentially more selective and well-tolerated treatment option. The drug’s clinical trial results have demonstrated its efficacy in improving sleep quality without causing significant adverse effects.
The Food and Drug Administration (FDA) has evaluated the abuse potential of daridorexant in preclinical models, recreational sedative drug users, and insomnia subjects. This evaluation is a standard part of the drug approval process, ensuring that medications are safe and not prone to misuse. The findings from these studies contribute to a comprehensive understanding of the drug’s risk-benefit profile.
Looking ahead, the next key milestone for Nxera Pharma will be the MFDS’s review of the MAA for daridorexant. The company anticipates a decision by 2027, which will determine whether the drug will be available to patients in South Korea. The successful launch of daridorexant in South Korea would further solidify Nxera Pharma’s position as a leading provider of innovative insomnia treatments. Investors and healthcare professionals will be closely watching the MFDS’s decision, as it could have significant implications for the treatment of insomnia in the region.
The company will continue to monitor the evolving landscape of insomnia treatment and explore opportunities to expand its product portfolio. With a strong commitment to research and development, Nxera Pharma is well-positioned to address the growing global need for effective sleep solutions. The submission of the MAA for daridorexant in South Korea represents a significant step forward in this ongoing effort.
Stay informed: For the latest updates on daridorexant and Nxera Pharma, please refer to the company’s official website and regulatory filings with the MFDS. We encourage readers to share their thoughts and experiences with insomnia treatments in the comments below.